STOCK TITAN

Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced its participation in several major healthcare conferences in November 2024. The company will present research on multiple drug candidates including Plozasiran at the American Conference on Pharmacometrics and American Heart Association Scientific Sessions. Key presentations focus on treatments for hypertriglyceridemia and familial chylomicronemia syndrome.

The company will also showcase research on Fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease at The Liver Meeting 2024. Additional presentations are scheduled at the UBS Global Healthcare Conference, TIDES Europe, and Jefferies London Healthcare Conference, covering various aspects of their therapeutic pipeline and platform technologies.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) ha annunciato la sua partecipazione a diverse importanti conferenze sanitarie nel novembre 2024. L'azienda presenterà ricerche su molteplici candidati farmaci, incluso Plozasiran, alla Conferenza Americana sulla Farmacometria e alle Sessioni Scientifiche dell'Associazione Cardiaca Americana. Le presentazioni principali si concentrano sui trattamenti per l'ipertrigliceridemia e il sindrome da chilomicronemia familiare.

L'azienda presenterà inoltre ricerche su Fazirsiran per la malattia epatica associata alla carenza di alfa-1 antitripsina durante l'Incontro sul Fegato 2024. Ulteriori presentazioni sono programmate alla Conferenza Globale UBS sulla Salute, a TIDES Europa e alla Conferenza Sanitaria di Jefferies a Londra, coprendo vari aspetti della loro pipeline terapeutica e delle tecnologie di piattaforma.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) ha anunciado su participación en varias conferencias importantes de salud en noviembre de 2024. La empresa presentará investigaciones sobre múltiples candidatos a fármacos, incluyendo Plozasiran, en la Conferencia Americana sobre Farmacometría y en las Sesiones Científicas de la Asociación Americana del Corazón. Las presentaciones clave se centran en tratamientos para la hipertrigliceridemia y el síndrome de quilomicronemia familiar.

La empresa también mostrará investigaciones sobre Fazirsiran para la enfermedad hepática asociada a la deficiencia de alfa-1 antitripsina en la Reunión del Hígado 2024. Presentaciones adicionales están programadas en la Conferencia Global de Salud de UBS, TIDES Europa y la Conferencia de Salud de Jefferies en Londres, abarcando varios aspectos de su cartera terapéutica y tecnologías de plataforma.

애로우헤드 제약 (NASDAQ: ARWR)은 2024년 11월에 여러 주요 의료 회의에 참여한다고 발표했습니다. 이 회사는 플로자시란 (Plozasiran)을 포함한 여러 치료 후보에 대한 연구 결과를 미국 약물 계량학 회의와 미국 심장 협회 과학 세션에서 발표할 예정입니다. 주요 발표는 고중성지방혈증 및 가족성 킬로미크론혈증 증후군 치료에 중점을 두고 있습니다.

회사는 또한 2024년 간 회의에서 알파-1 항트립신 결핍으로 인한 간 질환에 대한 파지르시란 (Fazirsiran) 연구 결과를 발표할 것입니다. UBS 글로벌 헬스케어 회의, TIDES 유럽, 제프리스 런던 헬스케어 회의에서 추가 발표가 예정되어 있으며, 이들의 치료 파이프라인 및 플랫폼 기술의 다양한 측면을 다룰 것입니다.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) a annoncé sa participation à plusieurs grandes conférences de santé en novembre 2024. L'entreprise présentera des recherches sur plusieurs candidats-médicaments, y compris Plozasiran, lors de la Conférence Américaine sur la Pharmacométrie et des Sessions Scientifiques de l'American Heart Association. Les présentations clés portent sur des traitements pour l'hypertriglycéridémie et le syndrome de chylomicronémie familiale.

L'entreprise présentera également des recherches sur Fazirsiran pour les maladies hépatiques associées à la carence en alpha-1-antitrypsine lors de la Liver Meeting 2024. D'autres présentations sont programmées à la Conférence Globale UBS sur la Santé, à TIDES Europe et à la Conférence de Santé de Jefferies à Londres, couvrant divers aspects de leur pipeline thérapeutique et des technologies de plateforme.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) hat seine Teilnahme an mehreren bedeutenden Gesundheitskonferenzen im November 2024 angekündigt. Das Unternehmen wird Forschungsarbeiten zu mehreren Arzneimittelkandidaten, darunter Plozasiran, auf der Amerikanischen Konferenz für Pharmakometrie und den Wissenschaftlichen Sitzungen der American Heart Association präsentieren. Die wichtigsten Präsentationen konzentrieren sich auf Behandlungen von Hypertriglyceridämie und dem familiären Chylomikronämie-Syndrom.

Das Unternehmen wird auch Forschung zu Fazirsiran bei leberbedingten Erkrankungen im Zusammenhang mit Alpha-1-Antitripsin-Mangel beim Liver Meeting 2024 präsentieren. Weitere Präsentationen sind auf der UBS Global Healthcare Conference, TIDES Europa und der Jefferies London Healthcare Conference geplant, die verschiedene Aspekte ihrer Therapie-Pipeline und Plattformtechnologien abdecken.

Positive
  • None.
Negative
  • None.

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

15th Annual American Conference on Pharmacometrics (ACoP 2024) – November 10-13, 2024

Title: Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemia
Presenter: Jack Shi
Session: Poster

Title: Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Atherosclerotic Cardiovascular Disease (ASCVD) in Patients with Mixed Hyperlipidemia
Presenter: Jack Shi
Session: Poster

UBS Global Healthcare Conference – November 11-14, 2024

Type: Fireside Chat Presentation
Date/Time: November 12, 2024, 3:30 p.m. PST

TIDES Europe – Oligonucleotide and Peptide Therapeutics – November 12-14, 2024

Title: Novel TRiM™ Platform for Oligonucleotide Delivery to Trabecular Meshwork via Local Intracameral Administration
Date/Time: November 14, 2024, 14:00 CET
Presenter: Jing Chen
Session: Oligonucleotide Discovery, Preclinical and Clinical

American Heart Association (AHA) Scientific Sessions 2024 – November 16-18, 2024

Title: PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP)
Date/Time: November 16, 2024, 2:04 pm CST
Presenter: Gerald Watts
Session: Featured Science: Novel Approaches to Managing Lipid Risk

Title: Plozasiran and Triglyceride Levels in Hypertriglyceridemia: Long-Term Efficacy and Safety Data from Subjects in an Open-Label Extension Trial (MUIR and SHASTA-2 OLE)
Date/Time: November 18, 2024, 10:45 am CST
Presenter: Christie Ballantyne
Session: New Insights in Lipids and lipid lowering therapies

The Liver Meeting 2024 - American Association for the Study of Liver Diseases (AASLD) – November 15-19, 2024

Title: Long-Term Safety and Efficacy of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Enrolled in the Phase 2 Placebo-Controlled SEQUOIA Trial
Date/Time: November 18, 2024, 8:00 am PST
Presenter: Virginia Clark
Session: Metabolic and Genetic Disease

Title: Digital Image Quantification of Collagen Proportionate Area Correlates with METAVIR Fibrosis Stage and Liver Stiffness Measurement Via FibroScan® in Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Date/Time: November 18, 2024, 8:00 am PST
Presenter: Cynthia Behling
Session: Metabolic and Genetic Disease

Title: Concordance of Histological and Liquid Chromatography Mass Spectrometry-Based Intrahepatic Z-Alpha-1 Antitrypsin (Z-AAT) Burden Assessments in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Date/Time: November 18, 2024, 8:00 am PST
Presenter: Rohit Loomba
Session: Metabolic and Genetic Disease

Jefferies London Healthcare Conference – November 19-21, 2024

Type: Fireside Chat Presentation
Date/Time: November 20, 2024, 8:00 am GMT

Presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.

Vince Anzalone, CFA

626-304-3400

ir@arrowheadpharma.com

Investors:

LifeSci Advisors, LLC

Brian Ritchie

212-915-2578

britchie@lifesciadvisors.com

Media:

LifeSci Communications, LLC

Kendy Guarinoni, Ph.D.

724-910-9389

kguarinoni@lifescicomms.com

Source: Arrowhead Pharmaceuticals, Inc.

FAQ

What conferences will Arrowhead Pharmaceuticals (ARWR) attend in November 2024?

Arrowhead will participate in six major conferences: ACoP 2024 (Nov 10-13), UBS Global Healthcare Conference (Nov 11-14), TIDES Europe (Nov 12-14), AHA Scientific Sessions (Nov 16-18), The Liver Meeting 2024 (Nov 15-19), and Jefferies London Healthcare Conference (Nov 19-21).

What will Arrowhead Pharmaceuticals (ARWR) present about Plozasiran at AHA 2024?

At AHA 2024, Arrowhead will present the PALISADE Phase 3 study results on Plozasiran for familial chylomicronemia syndrome and long-term efficacy data from the MUIR and SHASTA-2 open-label extension trials for hypertriglyceridemia.

What research will Arrowhead (ARWR) present at The Liver Meeting 2024?

At The Liver Meeting 2024, Arrowhead will present three studies on Fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease, including long-term safety data from the SEQUOIA trial and research on collagen assessment methods.

Arrowhead Research Corporation

NASDAQ:ARWR

ARWR Rankings

ARWR Latest News

ARWR Stock Data

2.48B
124.20M
4.47%
80.36%
7.51%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PASADENA